SAN DIEGO, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. today announced that the Company will present at the following investor conferences:
(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)
Live audio webcasts of these presentations will be accessible on the Investors page of the Company’s website at www.optimerpharma.com, under the investors section. Replays of these presentations will be available at the same location for 30 days following the meeting.
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of travelers’ diarrhea, a form of infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.
SOURCE Optimer Pharmaceuticals, Inc.
CONTACT: Christina Donaghy, Corporate Communications Manager, or John D.
Prunty, Chief Financial Officer & VP Finance, both of Optimer
Pharmaceuticals, Inc., +1-858-909-0736; or Jason I. Spark, Vice President
of Porter Novelli Life Sciences, +1-619-849-6005, for Optimer
Pharmaceuticals, Inc.
Web site: http://www.optimerpharma.com/
